Metrochem API Private Limited Metrochem API Private Limited

X

Find the latest Drugs in Development and Pipeline Prospector News of Harpoon Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Harpoon Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
4000 Shoreline Court, Suite 250 South San Francisco, CA 94080 650-443-7400
Telephone
Telephone
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Through the acquisition, Merck leverages Harpoon lead candidate HPN328 (MK-6070), which is being evaluated in Phase I/II clinical trial studies in combination with Atezolizumab for the treatment of Small-cell Lung Cancer.


Lead Product(s): MK-6070,Atezolizumab

Therapeutic Area: Oncology Product Name: HPN328

Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Merck & Co

Deal Size: $650.0 million Upfront Cash: Undisclosed

Deal Type: Acquisition March 11, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The acquisition will expand Merck's oncology portfolio by including HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors.


Lead Product(s): HPN328,Atezolizumab

Therapeutic Area: Oncology Product Name: HPN328

Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Merck & Co

Deal Size: $680.0 million Upfront Cash: $680.0 million

Deal Type: Acquisition January 08, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The Company intends to use the proceeds to fund its clinical development programs from its platforms, including ongoing as well as future late-stage clinical studies of HPN328, a TriTAC that binds to human and non-human primate DLL3, CD3ε, and albumin with similar affinities.


Lead Product(s): HPN328,Atezolizumab

Therapeutic Area: Oncology Product Name: HPN328

Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Soleus Capital

Deal Size: $150.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement October 23, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

HPN328, is a DLL3 targeting TriTAC®, which is investigated in combination with atezolizumab for the treatment of patients with small cell lung cancer.


Lead Product(s): HPN328,Atezolizumab

Therapeutic Area: Oncology Product Name: HPN328

Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 15, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA.


Lead Product(s): HPN217

Therapeutic Area: Oncology Product Name: HPN217

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: AbbVie Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement September 13, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

HPN217 targets B-cell maturation antigen (BCMA) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to kill tumor cells and investigated for Relapsed/Refractory Multiple Myeloma.


Lead Product(s): HPN217

Therapeutic Area: Oncology Product Name: HPN217

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 27, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The proceeds will be used to complete ongoing Phase 1 clinical studies for TriTAC® T cell engagers, including HPN217 (BCMA) in Phase 1 for patients with relapsed and refractory multiple myeloma, and HPN328 (DLL3), in Phase 1/2 for patients with multiple neuroendocrine tumors.


Lead Product(s): HPN217

Therapeutic Area: Oncology Product Name: HPN217

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: New Leaf

Deal Size: $25.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement March 27, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The updated interim results from the Phase 1 trial establish clinical proof of concept of HPN217 in heavily pretreated relapsed/refractory multiple myeloma and provide further clinical validation of our proprietary TriTAC T cell engager platform.


Lead Product(s): HPN217

Therapeutic Area: Oncology Product Name: HPN217

Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: AbbVie Inc

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 03, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

HPN328, a Tri-specific T cell Activating Construct (TriTAC®), is being evaluated as monotherapy in an ongoing open-label, multicenter two-part study to assess the safety, tolerability and pharmacokinetics in patients with advanced cancers associated with expression of DLL3.


Lead Product(s): HPN328

Therapeutic Area: Oncology Product Name: HPN328

Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 26, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the supply agreement with Roche as it enables us to investigate the impact of HPN328 on solid tumors in combination with atezolizumab and provide further insight into the capabilities of our TriTAC technology platform.


Lead Product(s): HPN328,Atezolizumab

Therapeutic Area: Oncology Product Name: HPN328

Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 02, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY